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Abstract: The heart is extensively innervated and its performance is tightly controlled by the nervous system. Cardiac 
innervation density varies in diseased hearts leading to unbalanced neural activation and lethal arrhythmia. Diabetic 
sensory neuropathy causes silent myocardial ischemia, characterized by loss of pain perception during myocardial 
ischemia, which is a major cause of sudden cardiac death in diabetes mellitus (DM). Despite its clinical importance, the 
mechanisms underlying the control and regulation of cardiac innervation remain poorly understood.  
We found that cardiac innervation is determined by the balance between neural chemoattractants and chemorepellents 
within the heart. Nerve growth factor (NGF), a potent chemoattractant, is induced by endothelin-1 upregulation during 
development and is highly expressed in cardiomyocytes. By comparison, Sema3a, a neural chemorepellent, is highly 
expressed in the subendocardium of early stage embryos, and is suppressed during development. The balance of 
expression between NGF and Seme3a leads to epicardial-to-endocardial transmural sympathetic innervation patterning. 
We also found that downregulation of cardiac NGF leads to diabetic neuropathy, and that NGF supplementation rescues 
silent myocardial ischemia in DM. Cardiac innervation patterning is disrupted in Sema3a-deficient and Sema3a-
overexpressing mice, leading to sudden death or lethal arrhythmias. The present review focuses on the regulatory 
mechanisms underlying cardiac innervation and the critical role of these processes in cardiac performance.  
Keywords: Cardiac nerve, nerve growth factor, Sema3a, arrhythmia, silent myocardial ischemia, sudden cardiac death.  
INTRODUCTION 
  Cardiac innervation density is altered in diseased hearts, 
as in cases of congestive heart failure and myocardial 
infarction [1-3]. Following myocardial injury, cardiac nerves 
undergo denervation, which may be followed by Schwann 
cell proliferation and reinnervation, leading to heterogeneous 
patterns of innervation [4, 5]. Abnormal sympathetic inner-
vation may trigger lethal arrhythmia through ion channel 
modulation in cardiomyocytes [3, 6, 7]. In fact, there is 
circadian variation in the frequency of sudden cardiac death 
(SCD) that parallels sympathetic activity. -blocker therapy 
prevents SCD secondary to ventricular tachyarrhythmia in 
ischemic heart disease or congestive heart failure [8, 9]. 
Immunohistochemical analysis of cardiac nerves in explan-
ted hearts of transplant recipients reveals a positive 
correlation between nerve density and the clinical history of 
ventricular tachyarrhythmia [3]. Cardiac sensory denervation 
can also cause silent myocardial ischemia, characterized by 
loss of pain perception during myocardial ischemia and 
frequently leading to SCD in patients with diabetes mellitus 
(DM) [10]. Despite the severity of these complications, the 
molecular mechanism that determines innervation density in 
diseased hearts is poorly understood. Moreover, little is 
known about the anatomical distribution of cardiac nerves 
and the molecular mechanism regulating innervation during 
development [11]. The present review focuses on the   
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regulatory mechanisms underlying cardiac innervation and 
the critical role of these processes in cardiac performance. 
ANATOMY OF CARDIAC NERVOUS SYSTEM 
  The cardiac sympathetic nerves extend from the 
sympathetic neurons of stellate ganglia, which are located 
bilateral to the vertebra. Sympathetic nerve fibers project 
from the base of the heart into the myocardium, and are 
located predominantly in the subepicardium of the ventricle 
[12, 13]. The central conduction system, which includes the 
sinoatrial node, atrioventricular node, and His bundle, is 
extensively innervated compared to the working myocar-
dium [13-16]. We, and others, report that regional differen-
ces in cardiac sympathetic innervation, known as innervation 
patterning, are highly conserved among species [13, 14, 17]. 
  The cardiac nervous system also involves afferent nerves. 
The sensory signals generated in the heart are conducted 
through cardiac afferent nerves, primarily thinly myelinated 
A-fibers and nonmyelinated C-fibers [18, 19]. The sensory 
nerve fibers project to the upper thoracic dorsal horn via 
dorsal root ganglia neurons [18, 19]. Unlike sympathetic 
innervation, the anatomy of cardiac sensory innervation was 
poorly characterized until our recent report [20]. Cardiac 
sensory innervation will be discussed in more detail later in 
this review.  
NERVE GROWTH FACTOR UPREGULATION 
CAUSES NERVE SPROUTING AND SUDDEN 
CARDIAC DEATH  
  Nerve growth factor (NGF) is a prototypic member of the 
neurotrophin family, the members of which are critical for 290    Current Cardiology Reviews, 2009, Vol. 5, No. 4  Ieda and Fukuda 
the differentiation, survival, and synaptic activity of the 
peripheral sympathetic and sensory nervous systems [21-23]. 
The level of NGF expression within innervated tissues 
corresponds to innervation density [24].  
  Our recent investigations, and those of others, show that 
NGF expression is altered in diseased hearts [1-3, 25]. 
Studies in animal models by Zhou et al. [26] reveal that NGF 
is upregulated following myocardial infarction (MI), 
resulting in the regeneration of cardiac sympathetic nerves 
and heterogeneous innervation. In a previous study we report 
that NGF is upregulated in cardiac hypertrophy, leading to 
sympathetic hyperinnervation and rejuvenation [27]. NGF 
infusion after MI enhances myocardial nerve sprouting and 
results in a dramatic increase in SCD and a high incidence of 
ventricular tachyarrhythmia [1]. These results demonstrate 
that NGF-induced augmentation of sympathetic nerve 
sprouting in diseased hearts leads to lethal arrhythmia and 
SCD.  
NERVE GROWTH FACTOR DOWNREGULATION IS 
CRITICAL FOR DIABETIC NEUROPATHY AND 
SILENT MYOCARDIAL ISCHEMIA 
  In contrast to sympathetic innervation, very little was 
known about sensory innervation and its alteration in 
diseased hearts. Visceral organs, including the heart, are 
believed to be rich in autonomic efferent innervation and 
poor in nociceptive afferent nerves [28]. Zahner et al. [29] 
report that vanilloid receptor-1-immunopositive sensory 
nerves are enriched in the epicardium and scarce in the 
myocardium. In immunohistochemical studies using anti-
calcitonin gene-related peptide antibody (CGRP), a sensory 
marker, we demonstrated, for the first time, that cardiac 
sensory innervation is rich at epicardial sites and in the 
ventricular myocardium [20, 30]. In a screen of several 
neurotrophic factors, we found that the development of 
cardiac sensory nerves parallels the production of NGF in 
the heart [31]. Cardiac nociceptive sensory nerves that are 
immunopositive for CGRP, including the dorsal root ganglia 
and the dorsal horn, are markedly retarded in NGF-deficient 
mice and rescued in mice overexpressing NGF specifically 
in the heart. Thus, NGF synthesis in the heart is critical for 
the development of the cardiac sensory nervous system [32].  
  The cardiac sensory nervous system is responsible for 
pain perception and in the initiation of the protective 
cardiovascular response during myocardial ischemia [18, 19, 
33, 34]. Cardiac sensory nerve impairment causes silent 
myocardial ischemia, a major cause of sudden death in DM 
patients [10]. Despite the severity of this complication, the 
alterations in cardiac sensory innervation and the molecular 
mechanism underlying sensory neuropathy in diabetic hearts 
is unclear [35-41]. To investigate whether NGF is involved 
in diabetic neuropathy, DM was induced with streptozotocin 
in wild-type (WT) mice and in transgenic mice that 
overexpressed NGF in the heart [20, 42-45]. Downregulation 
of NGF, CGRP-immunopositive cardiac sensory dener-
vation, and atrophic changes in dorsal root ganglia were 
observed in DM-induced WT mice, whereas these deterio-
rations were rescued in DM-induced NGF-transgenic mice. 
Cardiac sensory function, measured by myocardial ischemia-
induced c-Fos expression in dorsal root ganglia, was also 
downregulated by DM in the WT mice, but not in the NGF-
transgenic mice [19]. Direct gene transfer of NGF into the 
diabetic rat hearts improved cardiac sensory inner-vation and 
function according to the electrophysiological activity of 
cardiac afferent nerves during myocardial ische-mia (Fig. 1) 
[46, 47]. These findings demonstrate that DM-induced 
downregulation of NGF may lead to cardiac sensory neuro-
pathy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1).  NGF gene transfer restores impaired sensory 
innervation in diabetic hearts. 
Recording of impulse activity from cardiac sympathetic afferent 
nerves. Myocardial ischemia was induced at the time point 
indicated by arrows. Note that the response of cardiac afferent 
nerves was reduced in DM injected with p-con (control). The gene 
transfer of 50 μg p-NGF preserved cardiac sensory nerve function 
in DM. 
 
  Phase I and phase II clinical trials of systemic adminis-
tration of recombinant NGF reveal the safety and potential 
efficacy of this treatment for diabetic polyneuropathy, 
although a phase III trial showed no beneficial effects, 
possibly because the dosage and route of administration was 
suboptimal [48, 49]. It is possible that restriction of NGF 
dosage due to side-effects and the development of anti-NGF 
antibodies contributed to the lack of beneficial effects in the 
phase III clinical trial. To avoid these complications, gene 
transfer was used to directly administer the NGF gene into 
the heart. Both NGF- and CGRP-immunopositive nerves 
were reduced in diabetic hearts, thereby demonstrating the 
successful treatment of cardiac sensory neuropathy by NGF 
gene transfer. Consistent with our findings, the efficacy of 
NGF gene therapy has been reported in diabetic cystopathy 
and neuropathy of the footpad [49, 50]. Future studies on the 
reliability and efficacy of NGF  gene therapy are required 
before clinical trials can proceed.  Cardiac Innervation and Sudden Cardiac Death  Current Cardiology Reviews, 2009, Vol. 5, No. 4    291 
ENDOTHELIN-1-INDUCED NGF UPREGULATION 
IS ESSENTIAL FOR CARDIAC SYMPATHETIC 
INNERVATION 
  Although alteration in the level of NGF has a great 
impact on the clinical outcome in heart disease, the mole-
cular mechanisms underlying the regulation of NGF expres-
sion and sympathetic innervation are poorly understood. To 
address this issue, we performed a screen of several cardiac 
hypertrophic factors and found that ET-1 specifically upre-
gulates NGF expression in primary cultured cardiomyocytes 
[51]. Furthermore, we showed that ET-1-induced NGF 
augmentation was not observed in cardiac fibroblasts but 
was specific to cardiomyocytes, and identified signaling 
molecules involved in the ET-1/NGF pathway. 
  To study the effects of the ET-1/NGF pathway on the 
development of the cardiac sympathetic nervous system, we 
analyzed various gene-modified mouse models. NGF 
expression, cardiac sympathetic innervation, and norepine-
phrine concentration were reduced in ET-1-deficient mouse 
(Edn1
-/-) hearts, but not in the hearts of angiotensinogen-
deficient mice (Atg
-/-). In Edn1
-/- mice, the sympathetic 
stellate ganglia exhibited excessive apoptosis and displayed 
loss of neurons at the late embryonic stage [52]. Moreover, 
we demonstrated that cardiac-specific overexpression of 
NGF in Edn1
-/- mice overcomes sympathetic nerve retar-
dation (Fig. 2) [53]. These findings indicate that ET-1 is a 
key regulator of NGF expression in cardiomyocytes, and that 
the ET-1/NGF pathway is critical for sympathetic inner-
vation in the heart [54]. Given that ET-1 is strongly induced 
in myocardial infarction and cardiac hypertrophy, the ET-
1/NGF pathway may also be involved in NGF upregulation 
and nerve regeneration in pathological hearts.  
CARDIAC SYMPATHETIC INNERVATION PAT-
TERNING IS DETERMINED BY SEMA3A EXPRES-
SION 
  The growth-cone behavior of nerves is determined by 
coincident signaling between neural chemoattractants and 
chemorepellents, synthesized in the innervated tissue. While 
NGF plays critical roles in cardiac innervation as a chemo-
attractant, the neural chemorepellent that induces growth-
cone collapse and repels nerve axons is not found in the 
heart. Recently, we found that Sema3a inhibits neural growth 
and establishes appropriate innervation patterning in the 
heart [55].  
  Sema3a is a Class 3 secreted semaphorin and has been 
cloned and identified as a potent neural chemorepellent and a 
directional guidance molecule for nerve fibers [56-58]. For 
this reason, investigations were initiated to determine if 
cardiomyocytes produced Sema3a and if this protein played 
a role in sympathetic neural patterning and cardiac perfor-
mance. We analyzed the kinetics and distribution of cardiac 
sympathetic innervation in developing mouse ventricles [55]. 
Sympathetic nerve endings, immunopositive for the 
sympathetic marker, tyrosine hydroxylase (TH), appeared on 
the epicardial surface at embryonic day (E)15 and then 
gradually increased in number in the myocardium after 
postnatal day (P)7 and P42. Sympathetic nerves were more 
abundant in the subepicardium than in the subendocardium 
of the ventricular myocardium, suggesting the presence of an 
epicardial-to-endocardial gradient that is consistent with 
previous reports [12, 14-16]. We analyzed heterozygous 
Sema3a knocked-in lacZ mice (Sema3a
lacZ/+) to investigate 
the expression pattern of Sema3a and its relationship to 
innervation patterning in the heart. At E12, strong lacZ 
expression was detected in the heart, especially in the trabe-
cular components of the ventricles. By E15, lacZ expression 
was observed in the subendocardium, but not in the sube-
picardium, of the atria and ventricles. At P1 and P42, lacZ 
expression was reduced in certain regions and highlighted 
the Purkinje fiber network along the ventricular free wall 
[59, 60]. Quantitative RT-PCR of Sema3a in developing 
hearts revealed a linear decrease in the expression of Sema3a 
from E12 that corresponded with an increase in sympathetic 
innervation density. The negative correlation between the 
kinetics of Sema3a expression and sympathetic innervation 
indicates that Sema3a negatively regulates cardiac inner-
vation in developing hearts (Fig. 3).  
 
 
 
 
 
 
 
 
Fig. (2). Cardiac-specific overexpression of NGF overcomes the defects of cardiac sympathetic nervous system in Edn1
-/- mice. 
Immunostaining for TH in the hearts of Edn1
+/+, Edn1
-/- and Edn1
-/-/MHC-NGF mice. The reduced sympathetic innervation in Edn1
-/- hearts 
is rescued in Edn1
-/-/MHC-NGF hearts. Scale bar, 100 μm. 
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SEMA3A DEFICIENT MICE SHOW SINUS ARREST 
AND SUDDEN DEATH 
  To investigate whether Sema3a is critical for cardiac 
sympathetic nerve development, we analyzed Sema3a-defi-
cient mice (Sema3a
–/–) [55, 61, 62]. The WT hearts showed a 
clear epicardial-to-endocardial gradient of sympathetic 
innervation. By comparison, the sympathetic nerve density 
was reduced in the subepicardium and enhanced in the 
subendocardium of Sema3a
–/– mice, resulting in disruption of 
the innervation gradient in Sema3a
–/– ventricles. The 
Sema3a
–/–  mice also exhibited malformation of the stellate 
ganglia that extend sympathetic nerves to the heart.  
  Strikingly, we also found that most of the Sema3a
–/– mice 
died within the first postnatal week, with only 20% surviving 
until weaning [55, 61, 62]. To identify the cause of death and 
the effects of abnormal sympathetic neural distribution in 
Sema3a
–/– hearts, we performed telemetric electrocardio-
graphy and heart-rate variability analysis [63, 64]. In addi-
tion to multiple premature ventricular contractions, Sema3a
–
/– mice developed sinus bradycardia and abrupt sinus arrest 
due to sympathetic neural dysfunction (Fig. 4). 
SEMA3A-OVEREXPRESSION CAUSES 
VENTRICULAR TACHYARRHYTHMIAS DUE TO 
INNERVATION PATTERNING DEFECTS 
  We generated transgenic mice that overexpressed 
Sema3a specifically in the heart (SemaTG) to determine if 
the phenotype observed in Sema3a
–/– hearts is a secondary 
effect of stellate ganglia malformation [65]. This possibility 
was discounted as SemaTG mice showed reduced sym-
pathetic innervation and attenuation of the epicardial-to-
endocardial innervation gradient.  
 The  SemaTG mice died suddenly without symptoms at 
10 months of age. Sustained ventricular tachyarrhythmia was 
induced in SemaTG mice, but not in WT mice, after 
epinephrine administration, and programmed electrical 
stimulation revealed that SemaTG mice were highly 
susceptible to ventricular tachyarrhythmia (Fig. 4 and 5) [66, 
67]. The 1-adrenergic receptor density was upregulated and 
the cAMP response after catecholamine injection was 
exaggerated in SemaTG ventricles. Action potential duration 
was significantly prolonged in hypoinnervated SemaTG 
ventricles, presumably via ion channel modulation. These 
results suggest that the higher susceptibility of SemaTG mice 
to ventricular arrhythmia is due to catecholamine super-
sensitivity and prolongation of action potential duration, both 
of which can augment triggered activity in cardiomyocytes 
[68-72]. Thus, Sema3a-mediated sympathetic innervation 
patterning is critical for the maintenance of arrhythmia-free 
hearts.  
CONCLUSIONS 
  Cardiac nerves are highly plastic, and the balance 
between NGF and Sema3a synthesized in the heart deter-
mines cardiac innervation patterning (Fig. 5). ET-1 
upregulates NGF expression in cardiomyocytes, modulates 
nerve sprouting and plays critical roles in sympathetic nerve 
development [27, 54]. NGF is also important for sensory 
innervation, and NGF downregulation may result in silent 
myocardial ischemia and SCD in diabetic patients [20]. On 
the other hand, Sema3a inhibits neural growth and esta-
blishes appropriate innervation patterning in the heart. Both 
Sema3a deficiency and overexpression reveal lethal arrhy-
thmias and sudden death due to disruption of sympathetic 
innervation patterning, suggesting fine tuning of Sema3a is 
critical for cardiac function. Thus, identification of the   
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Inverse expression pattern of Sema3a and sympathetic innervation in mouse hearts. 
Double staining with TH (brown) and X-gal (blue) in P1 and P42 Sema3a
lacZ/+ hearts. Sympathetic nerves are restricted to the subepicardium 
at P1, but extend into the myocardium, coincident with downregulation of Sema3a at P42. Scale bar, 100 μm. Cardiac Innervation and Sudden Cardiac Death  Current Cardiology Reviews, 2009, Vol. 5, No. 4    293 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Cardiac innervation patterning and lethal arrhythmias. 
The crosstalk between cardiomyocytes and sympathetic neurons. 
Neurons synthesize norepinephrine, and cardiomyocytes secret 
NGF and Sema3a to control cardiac performance. (b) Appropriate 
Sema3a-mediated sympathetic innervation patterning is critical for 
the maintenance of an arrhythmia-free heart. SemaTG mice are 
highly susceptible to ventricular tachyarrhythmias. 
molecular mechanisms regulating cardiac innervation would 
improve our general understanding of cardiac performance 
and disease.  
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